Pulmonary hypertension as a sign of heart involvement in chronic kidney disease progression


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Nowadays pulmonary hypertension is considered as one of complications of chronic disease progression, which is associated with unfavorable long-term prognosis. Risk factors and pathogenesis of pulmonary hypertension are not fully characterized. Pathogenetic factors of pulmonary hypertension, associated with hypervolemia, hyperphosphatemia, uremia, uremic vasculopathy, and systolic and diastolic left ventricular dysfunction in chronic kidney disease are reviewed. Possible therapeutic approaches in pulmonary hypertension, associated with chronic kidney disease, are discussed.

Толық мәтін

Рұқсат жабық

Авторлар туралы

N. Solomakhina

I. Kutyrina

Email: GELIANNA@MAIL.RU

T. Rudenko

M. Vaslyeva

Әдебиет тізімі

  1. Мухин Н.А. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний // Вестник РАМН. - 2003. - № 11 - С. 50—55.
  2. Моисеев В.С. Кардиоренальные синдромы (патогенетические, клиникодиагностические, прогностические и терапевтические аспекты) // Терапевтический архив. - 2011. - № 12. - C. 5—11.
  3. Смирнов А.В. Кардио-ренальный континуум: патогенетические основы превентивной нефрологии // Нефрология. - 2005. - Т. 9, № 3. - С. 7—15.
  4. Schiffrin E.L. Chronic kidney disease. Effects on the cardiorenal system. // Circulation. - 2007. - Vol. 116. - P. 85—97.
  5. Ronco C. The cardiorenal syndrome // Blood Purif. - 2009. - Vol. 27. -P. 114-126.
  6. Garg A.X. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I//Kidney Int. - 2002. - Vol. 61. - P. 1486-1494.
  7. Hallan S.I. Screeningfor chronic kidney disease: which strategy?// J Nephrol. -2010. - Vol. 23. - P. 147-155.
  8. Sarnak M.J. Cardiovascular disease risk factors in chronic renal insufficiency // Clin Nephrol. - 2002. - Vol. 57. - P. 327-335.
  9. Go A.S. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N Engl J Med. - 2004. - Vol. 351. - P. 1296-1305.
  10. Levey A.S. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification // Ann Intern Med. -2003. - Vol. 139. - P. 137-147.
  11. Muntner P. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study // Am J Kidney Dis. - 2010. - Vol. 55. - P. 441-451.
  12. Thomas R. Chronic kidney disease and its complications// Prim Care. - 2008. -Vol. 35. - P. 329-344.
  13. Middleton J.P., Pun P.H. Hypertension, chronic kidney disease, and the development of cardiovascular risk: a joint primacy // Kidney Int. - 2010. -Vol. 77. - P. 753-755.
  14. Kramer H., Toto R., Peshock R. Association between chronic kidney disease and coronary artery calcification: the DALLAS Heart Study // J Am Soc Nephrol. - 2005. - Vol. 16. - P. 507-513.
  15. Hutchison J.A. Vascular calcification in dialysis patients // Prilozi. - 2007. -Vol. 28. - P. 215-224.
  16. Fabbian F. Pulmonary hypertension in dialysis patients: a cross-sectional Italian study // Int J Nephrol. - 2010. - Vol. 2011. - P. 283-475.
  17. Unal A., Sipahioglu M., Oguz F. et al. Pulmonary hypertension in peritoneal dialysis patients: prevalence and risk factors // Perit Dial Int. - 2009. - Vol. 29. - P. 191-198.
  18. Yigla M., Fruchter O., Aharonson D. et al. Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients // Kidney Int. - 2009. - Vol. 75. - P. 969-975.
  19. Havlucu Y., Kursat S., Ekmekci C. et al. Pulmonary hypertension in patients with chronic renal failure // Respiration. - 2007. - Vol. 74. - P. 503-510.
  20. Abdelwhab S. Pulmonary hypertension in chronic renal failure patients // Am J Nephrol. - 2008. - Vol. 28. - P. 990-997.
  21. Pabst S., Hammerstingl C., Hundt F. et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study // PLoS One. - 2012. - Vol. 7. - P. 305-310.
  22. Ramasubbu K. Deswal A., Herdejurgen C. et al. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance//Int J Gen Med. - 2010. -Vol. 3. - P. 279-286.
  23. Simonneau G. Robbins I.M., Beghetti M. et al. Updated clinical classification of pulmonary hypertension // J Am Coll Cardiol. - 2009. - Vol. 54. - P. 43-54.
  24. Amin M. Pulmonary hypertension in patients with chronic renal failure: role of parathyroid hormone and pulmonary artery calcifications // Chest. - 2003. - Vol.124. - P. 2093-2097.
  25. Acarturk G., Albayrak R., Melek M. et al. The relationship between arteriovenous fistula blood flow rate and pulmonary artery pressure in hemodialysis patients // Int Urol Nephrol. - 2008. - Vol. 40. - P. 509-513.
  26. Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients // Nephrol Dial Transplant. - 2012. - Vol. 27. -P. 3908-3914.
  27. Swaminathan S., Shah S.V. Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease // Kidney Int. - 2011. - Vol. 80. -P. 453-463.
  28. Dhaun N., Goddard J., Webb D.J. The endothelin system and its antagonism in chronic kidney disease // J Am Soc Nephrol. - 2006. - Vol.17. - P. 943-955.
  29. Kumbar L., Fein P.A., Rafiq M.A. et al. Pulmonary hypertension in peritoneal dialysis patients // Adv Perit Dial. - 2007. - Vol.23. - P. 127-131.
  30. Pilz S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies//Am J Kidney Dis. - 2011. - Vol.58. - P. 374-382.
  31. Wang Z., Chesler N.C. Pulmonary vascular wall stiffness: an important contributor to the increased right ventricular afterload with pulmonary hypertension // Pulm Circ. - 2011. -Vol. 1. - P. 212-223.
  32. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. // N Engl J Med. - 2004. - Vol. 351. - P. 1425-1436.
  33. Chen S. A role for the cell cycle phosphatase Cdc25a in vitamin D-dependent inhibition of adult rat vascular smooth muscle cell proliferation // J Steroid Biochem Mol Biol. - 2010. - Vol. 122. - P. 326-332.
  34. Schoppet M., Shroff R.C., Hofbauer L.C. et al. Exploring the biology of vascular calcification in chronic kidney disease: what’s circulating? //Kidney Int. - 2008. - Vol. 73. - P. 384-390.
  35. Passauer J., Pistrosch F., Bussemaker E. et al. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide // J Am Soc Nephrol. - 2005. - Vol. 16. - P. 959-965.
  36. Barst R.J., Rubin L.J., Long W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension //N Engl J Med. - 1996. - Vol. 334. - P. 296-301.
  37. Channick R.N., Simonneau G., Sitbon O. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study // Lancet. - 2001. - Vol. 358. -P. 1119-1123.
  38. Galie N., Ghofrani H.A., Torbicki A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension // N Engl J Med. - 2005. - Vol. 353. -P. 2148-2157.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>